BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 12958625)

  • 1. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454.
    Amirkhosravi A; Mousa SA; Amaya M; Blaydes S; Desai H; Meyer T; Francis JL
    Thromb Haemost; 2003 Sep; 90(3):549-54. PubMed ID: 12958625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis.
    Abulencia JP; Tien N; McCarty OJ; Plymire D; Mousa SA; Konstantopoulos K
    Arterioscler Thromb Vasc Biol; 2001 Jan; 21(1):149-56. PubMed ID: 11145947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XV454, a novel nonpeptide small-molecule platelet GIIb/IIIa antagonist with comparable platelet alpha(IIb)beta3-binding kinetics to c7E3.
    Mousa SA; Forsythe M; Bozarth J; Youssef A; Wityak J; Olson R; Sielecki T
    J Cardiovasc Pharmacol; 1998 Nov; 32(5):736-44. PubMed ID: 9821847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists.
    Mousa SA; Khurana S; Forsythe MS
    Arterioscler Thromb Vasc Biol; 2000 Apr; 20(4):1162-7. PubMed ID: 10764688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of anticoagulants and platelet inhibitors in cancer-induced thrombosis.
    Cloonan ME; DiNapoli M; Mousa SA
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):341-5. PubMed ID: 17473575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist.
    Quinn MJ; Cox D; Foley JB; Fitzgerald DJ
    J Pharmacol Exp Ther; 2000 Nov; 295(2):670-6. PubMed ID: 11046104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
    Chakrabarti S; Clutton P; Varghese S; Cox D; Mascelli MA; Freedman JE
    Thromb Res; 2004; 113(3-4):225-33. PubMed ID: 15140587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia.
    Mousa SA; Ahmad S
    Am J Hematol; 2007 Apr; 82(4):276-82. PubMed ID: 17039513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
    Quinn MJ; Murphy RT; Dooley M; Foley JB; Fitzgerald DJ
    J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template.
    Okumura K; Shimazaki T; Aoki Y; Yamashita H; Tanaka E; Banba S; Yazawa K; Kibayashi K; Banno H
    J Med Chem; 1998 Oct; 41(21):4036-52. PubMed ID: 9767641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GPIIb/IIIa inhibitors: from bench to bedside and back to bench again.
    Armstrong PC; Peter K
    Thromb Haemost; 2012 May; 107(5):808-14. PubMed ID: 22370973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.
    Badorc A; Bordes MF; de Cointet P; Savi P; Bernat A; Lalé A; Petitou M; Maffrand JP; Herbert JM
    J Med Chem; 1997 Oct; 40(21):3393-401. PubMed ID: 9341914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies.
    Storey RF; May JA; Wilcox RG; Heptinstall S
    Thromb Haemost; 1999 Oct; 82(4):1307-11. PubMed ID: 10544919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men.
    Müller TH; Weisenberger H; Brickl R; Narjes H; Himmelsbach F; Krause J
    Circulation; 1997 Aug; 96(4):1130-8. PubMed ID: 9286940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo--in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A.
    Klinkhardt U; Kirchmaier CM; Westrup D; Graff J; Mahnel R; Breddin HK; Harder S
    Clin Pharmacol Ther; 2000 Mar; 67(3):305-13. PubMed ID: 10741635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis.
    Amirkhosravi A; Amaya M; Siddiqui F; Biggerstaff JP; Meyer TV; Francis JL
    Platelets; 1999; 10(5):285-92. PubMed ID: 16801104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.